PKU HealthCare Corp., Ltd.

1. Primary objective: To evaluate the pharmacokinetic characteristics of the test and reference preparations after a single oral administration in healthy subjects in the fasting and postprandial state, and to evaluate the bioequivalence of the two preparations in humans. 2. Secondary objective: To investigate the safety of the test and reference preparations after oral administration in healthy subjects.

The main purpose of the study is to study the pharmacokinetics of the test preparation Moxifloxacin Hydrochloride Tablets (produced by Peking University Pharmaceutical Co., Ltd.) and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®, produced by Bayer HealthCare Manufacturing S.r.l.) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the oral bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation Moxifloxacin Hydrochloride Tablets and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®) in healthy subjects. The secondary purpose of the study is to evaluate the safety of the test preparation Moxifloxacin Hydrochloride Tablets (specification: 0.4 g) and the reference preparation Moxifloxacin Hydrochloride Tablets (Avelox®, specification: 0.4 g) in healthy subjects.

To investigate the pharmacokinetic characteristics of a single oral administration of one tablet of paliperidone sustained-release tablets provided by Peking University Pharmaceutical Co., Ltd. (test preparation, strength: 6 mg) in healthy subjects and a single oral administration of one tablet of paliperidone sustained-release tablets certified by Janssen-Cilag International NV (reference preparation, trade name: Reida®, strength: 6 mg) under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.